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ABSTRACT
A 24-year-old female patient with chronic dry cough,
without wheezing and other symptoms, was diagnosed
as atopic cough variant asthma (CVA) sensitized with
house dust (HD) mite. To investigate the effect of a
leukotriene (LT) receptor antagonist (pranlukast hydrate,
ONON 450 mg/day), cough score, respiratory function,
cough receptor sensitivity to capsaicin, airway inflamma-
tion evaluated by hypertonic saline inhalation and airway
reactivity to histamine were studied before and after
treatment for 4 weeks. Furthermore, the effect of a LT
receptor antagonist on HD allergen-induced broncho-
constrictive and cough responses was investigated.
Treatment with a LTreceptor antagonist resulted in disap-
pearance of cough, improvement of respiratory function,
decrease in eosinophil percentage in induced sputum
and increase in capsaicin and histamine threshold.
Although bronchoprovocation with HD extract induced
an immediate bronchoconstriction followed by cough
responses before treatment, inhibition of both broncho-
constrictive and cough responses was observed after
treatment. These results suggest that LT is involved in the
mechanism of cough in this patient with atopic CVA.
Key words: asthma, atopy, cough variant asthma,
leukotriene receptor antagonist.
Correspondence: Dr K Minoguchi, Department of Respirology,
Kihara Hospital, 1-16-13 Kitamagome, Ohta-ku, Tokyo 143,
Japan.
Received 16 September 1997. Accepted for publication
11 November 1997.
INTRODUCTION
It has been reported that chronic cough is the only mani-
fested clinical symptom in patients with so-called cough
variant asthma (CVA).1,2 Episodic wheezing is one of the
criteria of bronchial asthma, but there is no history of
wheezing in CVA patients. Although the precise mecha-
nisms responsible for the induction of cough in CVA
patients are not clear, bronchodilators, such as ~2­
agonists and theophylline are effective agents in relieving
couqh.?
Several chemical mediators have been reported to be
involved in allergic reactions, including histamine,
leukotrienes (LT), and thromboxane (Tx) A2.3 Indeed, recep-
tor antagonists for these chemical mediators have been
reported to improve asthma symptoms and also to inhibit
allergen-induced bronchoconstriction.vv ln humans, much
evidence suggests that LT is the major mediator responsible
for an immediate bronchial response after the inhalation of
an allergen. 5 Recently, it was reported that a Tx synthetase
inhibitor was a useful drug for the management of CVA,
but the effectiveness of a LT receptor antagonist has not
been clearly dernonstroted.?
In the present paper we report on a case in which a LT
receptor antagonist improved cough and airway reactivity
to both capsaicin and histamine and also improved
eosinophilic airway inflammation detected by hypertonic
saline-induced sputum. Furthermore, we demonstrate that
inhalation of house dust extract resulted in cough induc-
tion followed by an immediate bronchial response and
that the LT receptor antagonist inhibited both the allergen-
induced cough and the bronchial response. These results
suggest that inhalation of allergen results in the induction
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of cough and that LT is a major chemical mediator
involved in cough in this patient with atopic CVA.
WBC, white blood cells; BA, basophil; Stab, stabed form of leuko-
cyte; Seg, segmented form of leukocyte; Eo, eosinophils, Mo,
monocytes; Ly, lymphocytes; RBC, red blood cells; HB, hemoglobin;
Het, hematocrit; PLT, platelets; Tp, total protein; GOT, aspartate amino-
transferase; GPT, glutamate-pyruvate transaminase; LDH, lactate
dehydrogenase; y-GTp, y-glutamyl transpeptidase; T-Bil, total bilirubin;
BUN, blood urea nitrogen; Cr, creatinine; CRp, C-reactive protein.
A 24-year-old female patient visited Kihara hospital
because of a dry cough that had persisted for 3 months. She
had no history of asthma or allergic rhinitis. Her cough
usually began at night and often disturbed her sleep. The
patient exhibited no wheezing, sputum, nasal discharge,
fever or other symptoms, including gastroesophageal symp-
Table 2. Clinical course
Before ON ON
_0·___ · ____·· ___._. _______
Cough score (mean/week) 70 1
Spirometry
FVC (L) 3.53 3.8
%FVC 114 113
FEV] (L) 3.18 3.7
FEV1 % 90 92.2
\/50 (Lis) 3.80 4.39
\/25 (Lis) 1.71 2.29
PEF (L/min) 459 539
CR sensitivity (IlmollL) 15.6 250
Ratio of eosinophils in 8.7 3.1
induced sputum (%)
PC20 (llg/mL) 780 1660
toms. No abnormalities were detected by chest X-ray film,
electrocardiogram, analysis of arterial blood gas and
respiratory function.
Laboratory findings detected increases in IgE, specifi-
cally house dust-, house dust mite- (Der f and Der p),
Japanese cedar- and hinoki-specific IgE, in her serum
(Table 1). Because CVA was suspected, several allergic
examinations were performed. Cough receptor sensitivity
to capsaicin was investigated according to methods
described by Fujimura et a/.8 Airway inflammation was
determined by calculating the percentage of eosinophils in
hypertonic saline-induced sputum, as described previ-
ouslv? Airway reactivity to histamine and house dust was
examined by methods described previously.'? Briefly, the
patient inhaled doubling increasing concentration of hista-
mine or a diluted solution of house dust extract (Torii
Pharmaceuticals Co Ltd, Tokyo, Japan) for 2 min by tidal
breathing. Increasing concentrations of histamine or house
dust extract were administered until the forced expiratory
volume in one second (FEVd decreased by more than
20% of the baseline value. Peak expiratory flow (PEF) and
daily cough symptoms were monitored. A daily record of
cough symptoms, including cough frequency, measured
on a scale of 0-3 (0, no cough; 1, infrequent; 2, frequent;
3, very frequent); intensity, measured on a scale of 0-2
Cough score, respiratory function and several allergic examinations
were investigated before and after treatment with the leukotriene receptor
antagonist aNON (450 mg/day) for 4 weeks. Improvement of cough
score and respiratory function, including morning peak expiratory flow
(PEF) were noted after treatment. Although increases in cough receptor
(CR) sensitivity to capsaicin, airway reactivity to histamine (PC20) and the
percentage of eosinophils were noted before treatment, a remarkable
improvement of all examinations was observed after treatment. All exam-
inations were evaluated again 2 h after taking aNON (225 mg).
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; Vso,
V2S, expiratory flow at the half and last middle half of time, respectively.
6.4
18
12
264
16
0.36
12.6
0.9
144
107
4.2
34.07
26.60
21.40
21.40
49.67
7.70
0.2
499
3800
0.0
2.0
64.0
3.0
4.0
27.0
407 X 104
12.4
41.0
21.5 X 104
Biochemistry
TP (g/dL)
GOT (lUlL) .
GPT (lUlL)
LDH (lUll)
y-GTP (lUlL)
T-Bil (mg/dL)
BUN (mg/dL)
Cr (mg/dL)
Nc' (mEqlL)
0- (mEq/L)
K+ (mEq/L)
Serology and Immunology
CRP (mg/dL)
IgE (IU/mL)
RAST (UA/mL)
House dust 1
House dust2
Der. f.
Der. p.
Japanese cedar
Hinoki
Table 1. Laboratory findings on arrival
Hematology
WBC (lmm3)
Ba (%)
Stab (%)
Seg (%)
Eo (%)
Mo(%)
Ly (%)
RBC (lmm3)
Hb (g/dL)
Hct (%)
PLT (lmm3)
HD concentration
Fig. 1 Effect of a leukotriene (LT) receptor antagonist on (a)
bronchial obstruction and (b) cough after inhaling the allergen
house dust extract (HO; wt/vol). Bronchoprovocative inhalation
of HO immediately induced cough before obvious bronchocon-
striction. Two inhalations of 1:50 diluted concentrations of HO
resulted in an immediate bronchial response with audible wheez-
ing. After treatment with the LT receptor antagonist pranlukast
hydrate (aNON; 450 mg/day) for 4 weeks, the inhalation test
was performed again with pretreatment with aNON (225 mg)
2 h before challenge. Both cough and bronchoconstriction were
inhibited by pretreatment with aNON. The percent decrease in
FEY1 and the total number of coughs for 5 min after inhalation of
each dilution of HO are shown. (D), without aNON pretreat-
ment; (~), responses after aNON pretreatment.
(0, no cough; 1, weak; 2, strong), and dyspnea, measured
on a scale of 0-1 (0, no dyspnea; 1, dyspnea), were
recorded four times a day (morning, day time, evening,
night time). The mean cough score for the week was calcu-
lated. The results of these examinations are summarized in
Table 2. An increase in the percentage of eosinophils and
airway reactivity to histamine and a decrease in PEF were
observed. Capsaicin inhalation in this patient resulted in
data similar to those observed in healthy females.
Inhalation of house dust extract resulted in the induction of
cough immediately after challenge and a dose-dependent
increase in the number of coughs was observed (Fig. 1).
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After two inhalations of 1:50 diluted house dust extract, an
immediate bronchial response appeared and wheezing
was detected with frequent cough. Because the frequency
and intensity of the cough were so severe, inhalation of
a ~2-agonist was necessary. Bronchoconstriction and
cough were immediately improved by the inhalation of a
~2-agonist. A late bronchial response was not observed
after inhalation challenge.
Because LT is one of the major chemical mediators
responsible for the immediate bronchial response in
asthma, the patient was treated with a LT receptor antag-
onist (pranlukast hydrate (ONON), 450 mg/day; ONO
Pharmaceutical Co. Ltd, Tokyo, Japan) for 4 weeks and
all clinical tests were performed again. Treatment with the
LT receptor antagonist resulted in an improvement of the
cough score, PEF, cough receptor sensitivity to capsaicin,
percentage of eosinophils in induced sputum and airway
reactivity to histamine (Table 2). Furthermore, both the
house dust extract-induced cough and the immediate
bronchial response were markedly inhibited by pretreat-
ment with the LT receptor antagonist (Fig. 1).
DISCUSSION
Patients with a chronic cough and without a history of
wheezing and dyspnea but with normal baseline spiro-
metory and hyperreactive airway, have been diagnosed
as CVA. Characteristic of the cough in CVA patients is the
excellent response of the cough to bronchodilatory
agents, such as ~2-agonists and theophylline. Recent
guidelines for the diagnosis of asthma have emphasized
the existence of eosinophilic inflammation in the airway
that is closely associated with airway hvperrecctivitv.Ur':'
Although there was no history of wheezing, increases in
the percentage of eosinophils and airway reactivity to his-
tamine were detected in the patient in the present study.
Inhalation of allergen resulted in the induction of cough
followed by bronchoconstriction; both were relieved by
the inhalation of a ~2-agonist. These results demonstrate
that it is likely that chemical mediators released during
the immediate bronchial response may be responsible for
the induction of cough after the inhalation of allergen.
Considering recent reports, it is likely that the cough is
elicited on the basis of the cough receptor sensitivity and
bronchoconstriction.Jv" Patients with a chronic cough
without a hyperreactive airway often possess hypersensi-
tivity to inhaled capsaicin, the active ingredient of red
pepper that produces a cough by stimulating C-fiber
endinqs." Anti-histamine receptor 1 antagonists are
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often effective in relieving cough in these pctients." In
contrast, bronchodilators are often effective in patients
with CVA.2 This evidence suggests that broncho-
constriction caused by the chemical mediators released
from inflammatory cells may contribute to the mecha-
nisms that induce cough.
In atopic asthma, inhalation of allergen results in the
release of several chemical mediators, including histamine,
Tx, platelet activating factor and LT. The protective effects of
receptor antagonists for these chemical mediators have
revealed that LT is the major chemical mediator responsible
for allergen-induced airway obstruction." Although it has
been reported that LT receptor antagonists also have a pro-
tective effect against exercise-, aspirin- and cold air-induced
asthma, the effectivenessfor the cough observed in patients
with CVA has not yet been clearly demonstroted.F'"? In the
present study, we have shown that inhalation of allergen
resulted in the induction of cough before obvious broncho-
constriction and a dose-dependent increase in the
frequency of cough was elicited by the immediate bronchial
response in this patient with atopic CVA. Treatment with a LT
receptor antagonist for 4 weeks resulted in an improvement
of airway inflammation, airway reactivity to histamine
and cough receptor sensitivity to capsaicin. Furthermore,
remarkable inhibition of allergen-induced cough and
bronchial obstruction by pretreatment with the LT receptor
antagonist strongly supports LT as a major chemical media-
tor for eliciting cough in this patient. It is unlikely that the
allergen-induced cough response was suppressed by pre-
treatment with the LT receptor antagonist solely because of
its bronchodilator effect as few coughs were induced after
two inhalations of a 50: 1 dilution of house dust extract after
treatment when FEV1 had decreased by 7%. In contrast,
17 coughs were counted after inhalation of a 100:1 dilu-
tion extract before treatment when FEV] had decreased by
3.5%. The fact that cough receptor sensitivity to capsaicin
changed from 7.6 to 250 rnrnol/L also suggeststhat LTwas
involved in the cough receptor sensitivity and, thus, may
have led to an improvement of cough in this patient follow-
ing treatment with the LT receptor antagonist.
It has been reported that tachykinins, such as sub-
stance P and neurokinin A, are involved in cough
mechanisms. Inhalation of capsaicin results in the
release of tachykinins from the airway sensory nerves,
which induces cough in guinea pigs. 20 Inhalation of LTD4
caused bronchoconstriction and plasma exudation in
guinea pigs that were, in part, due to tachykinins
released from the airway sensory nerves, because
pretreatment with a specific neurokinin receptor antago-
nist significantly inhibited these responses." In healthy
human subjects, bronchoconstriction accompanied by
cough has been induced after inhalation of LTC4 and
LTD.4,22 Although we did not measure the concentration
of substance P in the sputum, previous studies and our
observations suggest that LT may release tachykinins
after the allergen is inhaled and, thus, the LT receptor
antagonist was effective in relieving cough in our
patient.
The relationship between airway cough receptor sen-
sitivity and airway reactivity to non-specific spasmogens
has been reported to be independent.P In the present
study, treatment with the LT receptor antagonist for
4 weeks resulted in an improvement of airway inflam-
mation and airway reactivity to histamine. We cannot
disregard the possibility that cough receptor sensitivity
to capsaicin was improved by an alteration of airway
inflammation. Further studies are necessary to elucidate
the relationship between the severity of airway inflam-
mation and cough receptor sensitivity.
In conclusion, in the present study we reported on a
case with atopic CVA in which treatment with a LT recep-
tor antagonist improved cough and cough receptor
sensitivity to capsaicin and inhibited allergen-induced
cough and bronchial obstruction.
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